Comparison study of two accepted chemotherapy options for women with uterine cancer that has returned.
The recurrence must be newly diagnosed with measurable disease greater than 1 centimeter. Prior adjuvant radiation is allowed. Hormonal therapy must be discontinued.
Exclusions include, but are not limited to: Prior chemotherapy for uterine sarcoma, no planned radiotherapy after chemotherapy and participant can not have a hypersensitivity to filgrastim.
“You had such excellent speakers here that what they did for me was made me less afraid... so that if anything happened to me, I would know the processes to go through and what to ask for to benefit me as a person.”
